Results 141 to 150 of about 37,085 (301)

The OtR tumor recurrence and metastasis model reveals doxorubicin‐induced tumor shrinkage doesn't guarantee prolonged survival

open access: yesAnimal Models and Experimental Medicine, EarlyView.
Tumor growth inhibition does not predict survival benefit in a clinically relevant metastasis model. Tumor local growth and systemic metastasis represent distinct biological processes. In the 4T1‐OtR model, although chemotherapy significantly suppresses primary tumor growth, it fails to prevent distant metastasis or extend overall survival.
Lingli Luo   +6 more
wiley   +1 more source

[Review of breast self-examination and breast self-awareness]. [PDF]

open access: yesAten Primaria
Bartolome-Moreno C   +2 more
europepmc   +1 more source

Expresión del factor del Silenciamiento de la Transcripción del Elemento Represor 1 (REST) en Cáncer de mama

open access: diamond
Lorena Cayetano‐Salazar   +5 more
openalex   +2 more sources

Trametinib in Adults with Neurofibromatosis Type 1‐Related Symptomatic Plexiform Neurofibromas

open access: yesAnnals of Neurology, EarlyView.
Objective Mitogen‐activated protein kinase kinase inhibitors have shown promising results in treatment of plexiform neurofibromas in neurofibromatosis type 1 patients, but data in adults are limited. The aim of this phase 2 study was to investigate the efficacy and safety of trametinib in adults with neurofibromatosis type 1.
D. Christine Noordhoek   +7 more
wiley   +1 more source

Detection of Aedes (Fredwardsius) vittatus Mosquitoes, Yucatán Peninsula, Mexico, 2025. [PDF]

open access: yesEmerg Infect Dis
Chan-Chable RJ   +3 more
europepmc   +1 more source

Mannose‐Modified Cationic Liposome‐Based mRNA Therapeutics for Improved Triple‐Negative Breast Cancer Immunotherapy

open access: yesAdvanced NanoBiomed Research, EarlyView.
Schematic illustration of mTEM8‐loaded cationic liposome (cLipo‐Man/mTEM8) therapeutics for improved triple‐negative breast cancer immunotherapy. Despite triple‐negative breast cancer (TNBC) is the most heterogeneous and aggressive subtype of breast cancer, immunotherapy is emerging as a promising therapy.
Kexin Deng   +10 more
wiley   +1 more source

[Labor and social repercussions on the quality of life of breast cancer survivors]. [PDF]

open access: yesAten Primaria
Palacín-Melús SE   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy